79 results about "Vitreous cavity" patented technology

An apparatus and minimally invasive method for removing fluid from a subretinal space to allow a detached retina to flatten. An apparatus, comprising a fluid withdrawal device and a guide for advancing and placing the device, is positioned on the exterior eye surface at the detachment site. Various embodiments of the apparatus are disclosed. Using the guide, the surgeon advances the device into the fluid-filled space and drains fluid, allowing the retina to flatten. Additional injection of saline or gas into the vitreous cavity normalizes intraocular pressure, and the patient is ambulatory immediately afterward. Unlike other retinal attachment techniques, in the inventive procedure the patient receives only a local anesthetic, and has no restraint on head movement.

Method and design of a dual-optics accommodating intraocular lens (IOL) for vision correction of adult and pediatric eyes after cataract surgeries are disclosed. For adult eyes, a positive accommodation amplitude greater than 3.5 diopter and preferably 4.0 to 10.0 diopter may be achieved by optimal configurations having the positive-power front-optics moves toward the cornea, whereas the negative power back-optics moves in the opposite direction. In contrast, a negative accommodation is required for pediatric eyes and may be achieved by a reversed configurations. The enhanced efficiency, up to 500%, is proposed by preferred embodiments based on new lens design formulas and calculation steps for the IOL power pre-determined by the measured ocular parameters including the corneal power, IOL position and the vitreous cavity length of the eye.

A retinal implant device to stimulate a retina of an eye thereby producing a specific effect in an eye, such as vision or drug treatment of a chronic condition is described. The retinal device is made of a retinal implant that is positioned subretinally and that contains a multitude of stimulation sites that are in contact with the retina. A connection carries the stimulating electrical signal or drug. The connection passes transretinally through the retina and into the vitreous cavity of the eye, thereby minimizing damage to the nutrient-rich choroid. The lead is attached to a source of drugs or electrical energy, which is located outside the eye. The lead passes through the sclera at a point near the front of the eye to avoid damage to the retina.

Eye wall anchored fixtures each including at least one elongated anchor member for driven lengthwise insertion into an eye's eye wall in a transverse direction to its thickness for supporting an intraocular device in the eye's vitreous cavity. Fixtures are preferably anchored in circumferential incisions in a human adult eye's pars plana preferably 3.5 mm posterior to its corneal limbus, and perpendicular to a circumferential incision. The fixtures are either generally L-shaped with a single elongated anchor member designed for withdrawal from an eye wall or self-anchoring thereinto, or generally T-shaped with a pair of oppositely directed self-anchoring elongated anchor members for sealing a throughgoing incision. Intraocular devices can be designed for intraocular drug delivery, for acquiring intraocular physiological measurements, and the like.

Eye wall anchored fixtures each including at least one elongated anchor member for driven lengthwise insertion into an eye's eye wall in a transverse direction to its thickness for supporting an intraocular device in the eye's vitreous cavity. Fixtures are preferably anchored in circumferential incisions in a human adult eye's pars plana preferably 3.5 mm posterior to its corneal limbus, and perpendicular to a circumferential incision. The fixtures are either generally L-shaped with a single elongated anchor member designed for withdrawal from an eye wall or self-anchoring thereinto, or generally T-shaped with a pair of oppositely directed self-anchoring elongated anchor members for sealing a throughgoing incision. Intraocular devices can be designed for intraocular drug delivery, for acquiring intraocular physiological measurements, and the like.

The invention relates to an application of a GMFB antibody, in particular, an application of the GMFB antibody in the preparation of drugs for treating diabetic retinopathy. The GMFB antibody is injected into the right eye of an STZ induced DM rat by a vitreous cavity injection technology, then PBS with an equal amount is injected into the left eye, after two weeks, the difference of visual functions of two eyes of the rat is detected by an ERG method, and the result shows that the visual function of the eyeball that is injected with the GMFB antibody is obviously improved, compared with thatof the eyeball that is not injected with the GMFB antibody. Then people find that the GFAP expression of the retina of the eyeball with the GMFB antibody is prominently reduced, TUNEL dyeing for detecting cell apoptosis is also weakened, and the result shows that the GMFB antibody injected into the vitreous cavity can be used as a target of DR early intervention to protect the visual function.

A method is provided for implanting, in an eye, apparatus having an electrode array including stimulating electrodes shaped to define distal tips protruding from the array, a plurality of photosensors, and driving circuitry, configured to drive the electrodes to apply currents to the retina. The method includes removing a lens of the eye and a vitreous body of the eye, creating a corneoscleral incision and inserting the apparatus through the corneoscleral incision into a vitreous cavity of the eye. During the inserting, an orientation of the distal tips is maintained pointing towards a cornea of the eye. Subsequently to the inserting, the apparatus is rotated such that the distal tips point towards a macula of the eye. Subsequently to the rotating, the apparatus is positioned epi-retinally, such that the distal tips of the electrodes penetrate the retina. Other applications are also described.

The invention relates to a long-acting voriconazole intraocular medicine release system which contains voriconazole and is characterized in that the intraocular medicine release system also contains biodegradable medicinal high-molecular auxiliary material; voriconazole and biodegradable medicinal high-molecular auxiliary material are mixed to form homogenized mixture; the weight ratio of biodegradable high-molecular auxiliary material and voriconazole is 0.1:0.9-0.9-0.1; the molecular weight of the biodegradable high-molecular auxiliary material is 5000-1000000Dalton. The biodegradable high-molecular auxiliary material is selected from poly(lactide-co-glycolide) and polylactic acid. The release period of the voriconazole intraocular medicine release system is a week to a year, has less medicine dosage, less times of administration, reduces the adverse reaction caused by the repeated injection of vitreous cavity and greatly improve the compliance of patients; if the vitreous body baseis implanted simultaneously during the excision operation of the central vitreous body, the complications of intraocular hemorrhage and retinal detachment caused by the repeated vitreous body puncture medicine-injection.

The invention relates to the technical field of biomedical gene treatment, and discloses a nucleotide sequence for coding human receptor tyrosine kinase Mer and application thereof. The nucleotide sequence disclosed by the invention and the nucleotide sequence shown in SEQ ID NO: 3 have more than or equal to 95% identity. The application proves that by using an AAV-MERTK drug for treatment, the retinal pathology symptoms of rats with retinitis pigmentosa caused by MERTK mutation can be remarkably improved, and retinal function recovery can be remarkably improved. The AAV-MERTK drug is injectedinto a vitreous cavity, MERTK can be efficiently expressed in a retinal pigment epithelium layer, and the thickness of a retinal outer nuclear layer is increased. Meanwhile, a retinal potential diagram shows that compared with a control group, the rats in an AAV-MERTK drug treatment group have strong response to stimulation. Therefore, the AAV-MERTK drug has the effect of preventing or treating the retinitis pigmentosa.

A method of treating a detachment of a retina of an eye, the method including the steps of injecting a substance into a vitreous cavity of the eye, the substance slowing flow of fluid through the vitreous cavity into a subretinal space to reduce a rate of accumulation of a subretinal fluid in the subretinal space to below a rate of removal of the subretinal fluid from the subretinal space by retinal pigment epithelium; and permitting the retinal pigment epithelium to reattach the retina. The invention also includes devices for practicing the method.

The invention discloses a minimally invasive quantitative controllable design for fetching silicone oil from eyes, provides a method for fetching silicone oil from eyes in a minimally invasive, quantitative and controllable manner, and relates to improvement of methods for medical operation. The method has the advantages that the method mainly aims to accurately control negative pressures in real time when the silicone oil is fetched on the premise that special equipment is omitted, the negative pressures can be quickly released when liquid of vitreous cavities is mistakenly sucked, and accordingly severe problems of mistaken suction of ocular tissues, collapse of eyeballs and the like can be solved; double negative pressure release links of a manual valve are regulated and controlled by a conventional negative-pressure sucker and the manual valve of a negative-pressure tube when continuous quantitative negative-pressure suction assistance is required, so that the method mainly can be implemented, and tissue injury can be reduced by the aid of 23G minimally invasive incision; the 23G puncture incision is adopted in the method, the head of a 1 ml syringe is connected with a 22G intravenous indwelling canula to enter the eyes to suck the silicone oil, a disposable sputum sucking tube is connected with the tail of the syringe, the tail of the sputum sucking tube is further connected with a disposable suction connecting tube and then is connected with the conventional wall type or vertical negative-pressure sucker, negative-pressure values are set by the negative-pressure sucker, and operators can flexibly adjust the negative pressures by means of mastering an opening degree of the manual valve; all service materials are common articles for operation rooms, and accordingly the method is convenient to popularize.

The invention relates to an anti-fungal ophthalmopathy sustained-release milli-microcapsule and the application thereof. The anti-fungal ophthalmopathy sustained-release milli-microcapsule contains voriconazole and is characterized in that the sustained-release milli-microcapsule also contains biodegradable pharmaceutical high-molecular auxiliary material; the voriconazolen and the biodegradable pharmaceutical high-molecular auxiliary material construct homogenized milli-microcapsule with the diameter of 100nm-100um; wherein, the voriconazolen accounts for 2%-50% of the total weight of the milli-microcapsule; the molecular weight of biodegradable pharmaceutical high-molecular auxiliary material is 5000-1000000Dolton. The pharmaceutical high-molecular auxiliary material is selected from poly(lactide-co-glycolide), polylactic acid, polylactic acid-glycolic acid. The anti-fungal ophthalmopathy sustained-release milli-microcapsule is widely applicable to the direct medicine delivery treatment in vitreous cavity or the ocular fungal infection prevention. The anti-fungal ophthalmopathy sustained-release milli-microcapsule treats fungal endophthalmitis through direct sustained-release vitreous cavity medicine delivery, needs less medicine dosage and effectively maintains the medicine concentration for 3 months after once medicine delivery so that the medicine economy is greatly improved. The medicine dosage applied on the ocular part is less when common voriconazolen injection is delivered systematically; patients cannot endure if the direct vitreous cavity injection needs to be conducted 3 times a day.

Intraocular drug dispenser includes an elongated support member with a pair of opposite ends for anchoring to opposite surfaces of an eye's eye wall, and a string of discrete drug containing capsules for individual time controlled release of their drug contents into an eye's vitreous cavity.

The invention discloses a recombinant adeno-associated virus-NADH dehydrogenase subunit 4 gene full length and a medicament for treating Leber hereditary optic neuropathy. The full length of the gene is shown in the nucleotide sequence of SEQ ID NO: 1. Wherein, the nucleotide sequence has a full length of 3824bp, which consists of a CAG promoter sequence, a coding sequence of ND4 with a Cox10 mitochondrial localization sequence and a UTR with a length of 625bp. The medicament is injected into the vitreous cavity of the eye for the treatment of Leber's hereditary optic neuropathy. The medicament of the present invention is injected into the vitreous cavity, can maintain vitality in the vitreous cavity, and can be efficiently transfected into optic nerve cells. The signal peptide at the front end of the protein N, Orientation guides the protein into the mitochondria, and the mature ND4 protein enters the mitochondria to play a role. Therefore, drugs are effective in the treatment of Leber hereditary optic neuropathy.

The invention relates to the technical field of stem cells, in particular to a retinal progenitor cell and a preparation thereof having a function of treating degenerative retinal diseases. The preservation number of the retinal progenitor cell provided by the invention is CGMCC NO.10419; and the retinal progenitor cell, which can keep a good proliferation ability and stem cell properties, can take a good curative effect on treating the degenerative retinal diseases. Experiments show that the retinal progenitor cell that the preservation number is CGMCC NO.10419, as being injected into the vitreous cavities of RCS rats, can take a protective effect and achieve multi-focal visual electric-physiology display on retinal outer nuclear layer cells; and in dark adaptation, potential change conducted by retinal nerve photoreceptor cells in a retinal progenitor cell injection group is more obvious than that in a group which is just injected with an HBSS (Hanks balanced salt solution) buffer solution. A water maze test also indicates that the visual function of the rats in the retinal progenitor cell injection group is improved. In addition, all rats injected with the retinal progenitor cell that the preservation number is CGMCC NO.10419 are free from abnormity.